Eurofins Scientific

A decent end to FY24: investors jittery with biopharma headwinds

31/01/25 -"During FY24, Eurofins’ revenue was in line with market expectations, but the EPS and FCF outperformed. The initial knee-jerk reaction was attributable to continued weakness in the Biopharma ..."

PDF page sample
Pages
48
Language
English
Published on
31/01/25
Download
You may also be interested by these reports :
03/12/25
Adecco offers levers for improvement, with expected progress on growth and margins across all divisions and additional upside from cost actions and ...
03/12/25
We have adjusted our 2025E EPS to reflect Q3 results, which exceeded our expectations. In Q4, organic revenue is expected to grow broadly in line ...
03/12/25
During its Investors Day, Bilfinger laid out an ambitious new financial roadmap through 2030, targeting annual revenue growth of 8–10% and an EBITDA ...
13/11/25
Bilfinger reported a solid and steady quarter marked by improved financial strength. Orders rose 1%, and revenue grew 8%. The EBITA margin reached ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO